Stockscreener 앱 받기
4.5599
1.51%
-0.0801
전일 마감가:
$4.64
열려 있는:
$4.67
하루 거래량:
1.62M
Relative Volume:
0.38
시가총액:
$1.36B
수익:
$38.03M
순이익/손실:
$-146.40M
주가수익비율:
-8.769
EPS:
-0.52
순현금흐름:
$-121.38M
1주 성능:
+10.92%
1개월 성능:
+23.85%
6개월 성능:
-8.42%
1년 성능:
+29.83%
1일 변동 폭
$4.44
$4.67
1주일 범위
$3.92
$4.85
52주 변동 폭
$1.8906
$6.515
앱셀레라바이오로직스 Stock (ABCL) Company Profile
명칭
Abcellera Biologics Inc
전화
(604) 559-9005
주소
150 W 4TH AVENUE, VANCOUVER
ABCL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
4.56 | 1.39B | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.81 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.12 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.70 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.33 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
342.01 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
앱셀레라바이오로직스 Stock (ABCL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | 재개 | Leerink Partners | Outperform |
| 2024-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-02-22 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 재개 | Piper Sandler | Overweight |
| 2023-02-28 | 개시 | Cowen | Outperform |
| 2022-12-15 | 개시 | Goldman | Buy |
| 2022-11-16 | 개시 | Truist | Buy |
| 2021-12-21 | 개시 | The Benchmark Company | Buy |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-01-05 | 개시 | Berenberg | Buy |
| 2021-01-05 | 개시 | Credit Suisse | Outperform |
| 2021-01-05 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | Stifel | Buy |
모두보기
앱셀레라바이오로직스 주식(ABCL)의 최신 뉴스
AbCellera Biologics (NASDAQ:ABCL) Trading Up 11.6%Here's Why - MarketBeat
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026 - Investing News Network
AbCellera Biologics (NASDAQ:ABCL) Stock Rating Lowered by Wall Street Zen - MarketBeat
Why AbCellera Biologics Inc. stock could rally in 2025High Dividend Yield Stocks & Invest Like A Pro - bollywoodhelpline.com
Is AbCellera (ABCL) Quietly Recasting Its Platform As A Menopause-Focused Drug Developer? - simplywall.st
Aug Reactions: What is the implied volatility of Sonida Senior Living IncMarket Movers & Weekly Hot Stock Watchlists - baoquankhu1.vn
Citizens Financial Group Inc. RI Acquires Shares of 261,890 AbCellera Biologics Inc. $ABCL - MarketBeat
AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026 - Yahoo Finance
AbCellera Biologics Inc Doses First Patients in Phase 2 Trial for ABCL635 - TradingView — Track All Markets
AbCellera Biologics (NASDAQ:ABCL) Shares Down 5.6%Should You Sell? - MarketBeat
AbCellera begins phase 2 trial of non-hormonal menopause treatment By Investing.com - Investing.com Nigeria
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause - BioSpace
AbCellera begins phase 2 trial of non-hormonal menopause treatment - Investing.com
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL6 - PharmiWeb.com
AbCellera (ABCL) Advances Clinical Trial for Menopause Treatment - GuruFocus
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up on Analyst Upgrade - MarketBeat
Bear Alert: Is AbCellera Biologics Inc stock forming a triangle patternJuly 2025 Drop Watch & Smart Allocation Stock Tips - baoquankhu1.vn
AbCellera Biologics (NASDAQ:ABCL) Rating Increased to Hold at Wall Street Zen - MarketBeat
A Look At AbCellera Biologics (ABCL) Valuation After Bruker Settlement And Board Appointment - simplywall.st
Will AbCellera Biologics Inc. stock return to pre crisis levels2025 Pullback Review & Weekly Watchlist of Top Performers - ulpravda.ru
Can AbCellera Biologics Inc. stock maintain operating marginsJuly 2025 Macro Moves & Safe Capital Growth Plans - Улправда
How AbCellera Biologics Inc. stock performs in weak economyJuly 2025 WrapUp & Safe Capital Growth Plans - Улправда
Can AbCellera Biologics Inc. stock hit analyst price targetsMarket Correction Analysis & Maximize Returns With Insights - Улправда
AbCellera (ABCL) Loses Chief Commercial Officer to Viking Therap - GuruFocus
AbCellera Biologics (NASDAQ:ABCL) Trading Up 9.2%Still a Buy? - MarketBeat
AbCellera settles patent litigation with Bruker over microfluidic device tech - MSN
AbCellera Biologics (NASDAQ:ABCL) Cut to Sell at Wall Street Zen - MarketBeat
Is AbCellera Biologics Inc a good long term investmentMid Cap Growth Trends & These 3 Stocks Could Change Your Portfolio - earlytimes.in
MACD Cross Could Confirm Trend in Sancode Technologies LimitedEmerging Market Stocks & Unlock Patterns Humans Can’t See - earlytimes.in
Update Recap: How AbCellera Biologics Inc stock performs in weak economyExit Point & Real-Time Volume Analysis Alerts - moha.gov.vn
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Recommendation of "Hold" by Analysts - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Upgraded at Wall Street Zen - MarketBeat
We're Not Worried About AbCellera Biologics' (NASDAQ:ABCL) Cash Burn - Yahoo Finance
AbCellera: Losing Its Undeserved Premium (NASDAQ:ABCL) - Seeking Alpha
AbCellera Appoints Dr. Stephen Quake to Board - MSN
Why AbCellera Biologics Inc. stock is in analyst buy zoneMarket Activity Report & High Accuracy Investment Entry Signals - Улправда
Can AbCellera Biologics Inc. stock beat analyst upgrades2025 Trading Volume Trends & Verified Stock Trade Ideas - Улправда
Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? - MSN
AbCellera Biologics (STU:8QQ) EV-to-OCF : -6.77 (As of Dec. 22, 2025) - GuruFocus
AbCellera Gets $36M In Cell Research Patent Settlement - Law360
Buyout Rumor: How AbCellera Biologics Inc. stock performs in weak economyCEO Change & Weekly High Potential Alerts - DonanımHaber
Published on: 2025-12-19 14:45:34 - Улправда
AbCellera settles patent dispute with Bruker for $36 million upfront By Investing.com - Investing.com India
a2025-12x18brukerlitigat.htm - SEC.gov
AbCellera Secures Global Settlement and Patent License Deal - TipRanks
AbCellera Biologics Inc Settles Patent Litigation with Bruker - TradingView — Track All Markets
AbCellera stock jumps after settlement with Bruker in patent dispute By Investing.com - Investing.com South Africa
AbCellera stock jumps after settlement with Bruker in patent dispute - Investing.com
AbCellera Biologics (NASDAQ:ABCL) Trading 6.7% HigherHere's What Happened - MarketBeat
앱셀레라바이오로직스 (ABCL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.39%
1.60%
자본화:
|
볼륨(24시간):